The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•11 February 2026•

1 min read

uniQure Faces Class Action Lawsuit Over Alleged FDA Approval Misrepresentations

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Rosen Law Firm has announced a class action lawsuit against uniQure N.V. (NASDAQ: QURE) on behalf of shareholders. The lawsuit targets investors who purchased ordinary shares between September 24, 2025, and October 31, 2025. It alleges that uniQure misrepresented its business operations, specifically concerning FDA approval for its Pivotal Study design. Furthermore, the suit claims the company failed to disclose the need for additional studies, which impacted its Biologics License Application (BLA) timeline. Shareholders who incurred significant losses are urged to contact the firm by April 13, 2026, to understand their rights. This legal action introduces significant uncertainty and potential financial penalties for uniQure, casting a bearish outlook on its stock.